Home » Topics » BioWorld Science

BioWorld Science
RSS

Clinical efficacy of a BAY-43-9006 combination regimen in advanced melanoma

June 18, 2004

Vasogen updates Celacade phase III program

June 18, 2004

Enzon strengthens pipeline during Q3 through Onco TCS addition

June 18, 2004

NCX-911 may benefit ED patients with dysfunctional endogenous NO production

June 18, 2004

Treatment options for restless legs syndrome

June 18, 2004

Dopamine D4 receptor agonist ABT-724 may offer safe and effective treatment of erectile dysfunction

June 18, 2004

GPC Biotech achieves significant progress in anticancer drug programs during first quarter

June 18, 2004

Novel fructose 1,6-bisphosphatase inhibitor lowers blood glucose in vivo

June 18, 2004

Polyvalent vaccine reported to improve survival in advanced melanoma

June 18, 2004

Bavarian Nordic highlights Imvamune progress

June 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...